Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 4/20 | 0.56 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.54 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.54 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.53 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.49 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.49 |
| ▸ | AKT2 | P31751 | 2/20 | 0.47 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13058689 | 1.00 | AKT1 (0.56) | AKT1PLCG2GPR55SMPD1NR5A2 | |
| SCHEMBL13058699 | 1.00 | AKT1 (0.56) | AKT1PLCG2GPR55SMPD1NR5A2 | |
| SCHEMBL13058682 | 0.98 | AKT1 (0.56) | AKT1PLCG2GPR55SMPD1NR5A2 | |
| SCHEMBL13058685 | 0.98 | AKT1 (0.56) | AKT1PLCG2GPR55SMPD1NR5A2 | |
| SCHEMBL13058687 | 0.95 | AKT1 (0.53) | AKT1PLCG2GPR55SMPD1NR5A2 | |
| SCHEMBL12285595 | 0.92 | PLCG2 (0.65) | AKT1PLCG2GPR55SMPD1NR5A2 | |
| SCHEMBL30898873 | 0.92 | PLCG2 (0.65) | AKT1PLCG2GPR55SMPD1NR5A2 | |
| SCHEMBL15090908 | 0.92 | PLCG2 (0.65) | AKT1PLCG2GPR55SMPD1NR5A2 | |
| SCHEMBL13058760 | 0.91 | AKT1 (0.49) | AKT1PLCG2GPR55SMPD1AKT2 | |
| SCHEMBL13058764 | 0.90 | AKT1 (0.48) | AKT1PLCG2GPR55SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297156-A1 | ANALOGUES OF PHOSPHATIDYLINOSITOL MANNOSIDES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297156-A1 | ANALOGUES OF PHOSPHATIDYLINOSITOL MANNOSIDES | PIK3CA, PIK3CB, PIK3CG | AKT1 260/4885PLCG2 16/4885GPR55 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.